Paris & New York, 16 October 2017
Quantum Genomics nominated for the Galien MedStartUp Award for the innovative design of its NEW-HOPE trial
Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company that specialises in developing a new class of medications that act directly on the brain to treat hypertension and congestive heart failure, is announcing today that it has been nominated for the 2017 Galien MedStartUp Awards in the category ‘Best Innovative Trial Design'.
Quantum Genomics was selected alongside its clinical research partner Medpace for the design of its NEW-HOPE phase II trial, which tests the efficacy of the candidate drug QGC001 in treating arterial hypertension. The trial, to be conducted at 25 hospitals in the United States, will study 250 hypertensive patients who are overweight or obese and have profiles that make them particularly likely to have complicated, or even resistant, cases of hypertension. Half of the patients will be from American minority groups (African-Americans, Hispanics, Asians).
‘We are truly honoured to be one of the three start-ups still in the running in the “Best Innovative Trial Design” category, with the winner to be announced on 26 October in New York. This nomination is in recognition of many things: our inclusion in this trial of segments of the population that are rarely targeted, the quality of our medical teams, the reputation of our clinical research partner, and our significant efforts to bring our therapeutic innovation to patients as fast as possible,' said Lionel Ségard, ceo of Quantum Genomics.
Dr Catherine Llorens-Cortes, a pioneer of research on the brain renin-angiotensin system and co-inventor of cerebral aminopeptidase A inhibitors currently being developed by Quantum Genomics, previously won the Galien France Award in 2014 for her research. She directs the INSERM research group for ‘Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions' at the Collège de France.
Through MedStartUp, the Galien Foundation, established in 1970, encourages and gives awards to international partnerships between innovative French and North American companies, with a focus on innovation, scientific excellence, and business ambitions in the area of health.
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company specialising in the development of a new class of cardiovascular drugs based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on its 20-plus years of basic and clinical research at some of the largest French laboratories (The French National Institute of Health and Medical Research (INSERM), the French National Centre for Scientific Research (CNRS), the Collège de France, and Paris-Descartes University). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of arterial hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for congestive heart failure (one in two patients diagnosed with congestive heart failure dies within five years). Based in Paris and New York, the company is listed on the Euronext Growth exchange in Paris (FR0011648971 - ALQGC) and trades on the OTCQX market in the United States (symbol: QNNTF). For more information, visit www.quantum-genomics.com. Follow us on Twitter and Linkedin.
Chairman and CEO
+33 (0)1 85 34 77 70
CFO - Investor Relations
+33 (0)1 85 34 77 70 - firstname.lastname@example.org
Media Relations and Scientific Communications
+33 (0)6 50 92 21 56 - email@example.com
+33 (0)6 85 82 41 95 - firstname.lastname@example.org
|Edison Advisors (U.S.)|
+1 (646) 653-7035 - email@example.com